Decoding how cancer rewires its metabolism, its microenvironment, and its response to radiation.
Our laboratory studies how adaptive metabolic reprogramming shapes the cancer transcriptome and proteome during metastasis and therapy resistance, with a parallel translational focus on the mechanisms driving lung, breast, brain, and hepatobiliary–pancreatic malignancies. We also provide translational pathology support to colleagues across NYCU and Taipei Veterans General Hospital.
Tumor microenvironment remodeling through macrophage secretomes and polarization states, and how these signals feed back into tumor cell behavior and immune evasion.
TME · Macrophage PolarizationNon-enzymatic and enzymatic roles of aldolase isoforms (ALDOA/ALDOC/ALDOB), the VHL–glycolysis axis, purine/pyrimidine biosynthesis, and lactylation-driven epigenetic regulation in tumor progression.
ALDOA · VHL · GlycolysisCellular imaging and histomorphological approaches to radiation response, ferroptosis, and immune infiltration, applied to glioblastoma, cholangiocarcinoma, and renal cell carcinoma.
Radiobiology · Cellular ImagingSeven research themes arranged as a radiation trefoil — every building a project, paper or program, every golden arc a collaboration. Explore the lab as a map.
Enter the island →Every claim traced to a clean experiment, a proper control and a reproducible figure — before it reaches a manuscript.
We follow metabolism wherever it leads: from a single enzyme to the microenvironment, and from the bench to the patient's pathology slide.
Training scientists is the lab's longest-lasting output. Students and visitors are given real questions, real ownership and real credit.
Single-year impact list, 2026 — Clinical Medicine · Oncology & Carcinogenesis.
View profile →h-index rank 462 among 800,382 scholars in the specialty (top 0.09%); Quality top 0.13%, Impact top 0.18%. Life Sciences: top 0.36% for Quality.
Field: Life Sciences · Discipline: Biochemistry| Scope | Scholars ranked | Productivityrank · top % | Impact (citations)rank · top % | h-indexrank · top % | Qualityrank · top % |
|---|---|---|---|---|---|
| Overall (All Fields) | 9,375,746 | 199,5652.13% | 61,3560.65% | 33,5870.49% | 58,7400.63% |
| Life Sciences | 1,144,606 | 12,2251.07% | 5,4210.47% | 2,3430.3% | 4,0860.36% |
| Biochemistry | 83,308 | 7130.86% | 3070.37% | 1210.21% | 2350.28% |
| Specialties | |||||
| Cancer | 800,382 | 5,1100.64% | 1,4530.18% | 4620.09% | 1,0570.13% |
| Lung cancer | 119,073 | 6,5385.49% | 1,6231.36% | 1,2963.45% | 2,3912.01% |
| Glioblastoma | 42,645 | 2,0434.79% | 1,3773.23% | 3683.06% | 9512.23% |
| Metastasis | 102,454 | 1,8611.82% | 3,8743.78% | 2,98521.28% | 2,9492.88% |
| Colorectal cancer | 126,680 | 9,7517.7% | 9,8847.8% | 7,12325.76% | 10,0927.97% |
| Biosensor | 49,450 | 4,0538.31% | 2,0244.09% | 1,6287.43% | 2,3124.68% |
| Magnetic resonance imaging | 144,460 | 14,0799.82% | 4,1722.89% | 1,1272.62% | 4,2782.96% |
| Cell death | 68,991 | 8861.28% | 3,4234.96% | 3312.18% | 8071.17% |
| Biomarker | 259,377 | 15,2845.99% | 2,7651.07% | 9121.58% | 2,9641.14% |
| Platinum nanoparticle | 2,694 | 572.15% | 1154.27% | 10.91% | 240.87% |
| Protein | 448,305 | 44,74210.01% | 50,77611.38% | 4,6332.97% | 21,1014.71% |
| Neoplasm | 398,798 | 74,07018.58% | 2,3670.59% | 21,21324.14% | 17,5424.4% |
| Cancer immunotherapy | 62,422 | 7,68912.34% | 22,83236.58% | 3,56828.21% | 11,19717.94% |
| Cancer cell | 115,173 | 32,76928.51% | 40,93735.59% | 4,80629.08% | 33,19928.82% |
| Squamous cell carcinoma | 63,181 | 23,23239.85% | 10,28516.31% | 1,95819.98% | 12,76520.22% |
Source: ScholarGPS® Ranking Analytics, 2026. Evaluation period: prior 5 years; citation counts exclude self-citations; author weighting: weighted. “Top %” is the percentile among scholars ranked in the same scope. Productivity = weighted publications; Impact = weighted citations; Quality = composite Z score.